



Q1 2013 SALES

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012.

Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

€ millions	2013	2012	Change
Q1 sales	75.5	77.0	-2.0%
Q1 sales <i>At constant exchange rates</i>	76.2	77.0	-1.0%
Q1 sales <i>At constant exchange rates and consolidation scope (like for like)</i>	76.0	77.0	-1.4%

The Vétoquinol Group posted Q1 2013 sales of €75.5 million, down 2.0% compared to the same period last year and down 1.0% at constant exchange rates. Exchange rates had a negative impact (-1.0%) on Q1 2013 sales.

At Group level, the livestock sector was down 4.2%, whilst sales of companion animals products improved slightly (+0.4%).

In Europe, where the market remains sluggish, Vétoquinol saw its sales drop by 3.2%. Asia Pacific and the Americas registered organic growth of 5.6% and 0.7% respectively, bringing these regions' share of total Group sales up to 38.6% for Q1 2013, compared to 37.9% for Q1 2012.

The first quarter sales results do not benefit from the Group's strategic drivers yet. Sales of reference products were up 5.1% in Q1 2013 vs Q1 2012.

With a robust financial structure to support its future growth, the Vétoquinol Group is focusing on the successful implementation of its strategic plan.

At present, no known event since January 1, 2013 has had an impact on the Group's financial position as presented in its 2012 financial statements.

The Group's strong financial structure was further bolstered by the first quarter 2013 operating results. The Group net cash on hand continues to be solid.

Next update: H1 2013 sales, July 16, 2013 (after market close)

For immediate release

About Vétoquinol

Vétoquinol is a leading global operator in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and markets veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol has over 1,800 employees.

Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Investor Relations

Marie-Josée AUBRY-ROTA

Tel.: 03 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor Relations

Emmanuel DOVERGNE

Tel.: 01 56 43 44 63

emmanuel.dovergne@keima.fr

Media Relations

Alix HERIARD DUBREUIL

Tel.: 01 56 43 44 62

alix.heriard@keima.fr